Under the terms of the agreement announced Tuesday, Pfizer will pay an upfront fee followed by subsequent regulatory and sales milestones. The deal centers on ecnoglutide, a GLP-1 analog developed by Sciwind. While the drug has already received the green light from Chinese regulators for the treatment of type 2 diabetes, its potential as a weight-loss treatment remains the primary driver of the collaboration as Pfizer looks to challenge rivals in the surging obesity market.

Expanding the Metabolic Portfolio

Jean-Christophe Pointeau, president of Pfizer China, described the move as a significant milestone in the company's long-term strategy to expand its metabolic footprint. The move comes as global pharmaceutical leaders race to establish a foothold in China, where the demand for GLP-1 therapies is expected to mirror the explosive growth seen in Western markets. The deal with Hangzhou Sciwind Biosciences allows Pfizer to bypass some of the initial development hurdles in a highly competitive local landscape.

This partnership highlights a growing trend of cross-border collaborations between domestic Chinese biotechs and international drugmakers. Sciwind’s deal follows a massive $8.5 billion milestone agreement between Innovent Biologics and Eli Lilly earlier this month, signaling a period of intense consolidation and licensing activity within the Chinese healthcare sector. According to the statement released on WeChat, the ecnoglutide review process for obesity is currently ongoing.